Developer docs
API playgroundTry for free, no card

Search company profiles

Asalyxa Bio

Full company profile

uuid0002ek8

Namestring
Asalyxa Bio
Legal namestring
Asalyxa Bio
Websiteurl
asalyxabio.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Asalyxa Bio is a privately held, preclinical-stage biotechnology company founded in 2020 and headquartered in Southfield, Michigan. The company is focused on developing therapeutics that target neutrophils — the most abundant class of white blood cells and central effectors of inflammatory and innate immune responses — for application in diseases characterized by high unmet medical need. According to available firmographic data, the company employs between 11 and 50 people and operates as a for-profit entity with no public-market listing. The technology platform is positioned as a neutrophil-targeting drug delivery or modulation approach, but the available input contains no detailed description of the underlying scientific mechanism, specific product candidates, target indications, development stage, or intellectual property estate (no patents or trademarks were disclosed).

The company is led by a four-person executive team composed of co-founder and CSO Lola Eniola-Adefeso — whose background appears rooted in biomedical engineering research — alongside co-founder and CEO Marc Appel, Chief Operating Officer Ryan Fox, and Head of Corporate Development John Freshley. This composition is consistent with an early-stage biotech balancing scientific leadership with operational and business development capacity. There are no disclosed clinical trial programs, partnerships, licensing deals, or commercial products in the source data, and the company's revenue model is not articulated. Asalyxa Bio's only documented capital event is a $2,000,000 seed funding round closed on February 23, 2021, led by Research Bridge Partners with participation from Ann Arbor SPARK, Biosciences Research and Commercialization Center (BRCC), Invest Detroit Ventures, LoftyInc Capital, Michigan Rise, and Woodward Angels. As is typical for early-stage biotech, the implied business model is venture-funded R&D with eventual value realization through outlicensing, partnership, acquisition, or independent commercialization — none of which have materialized in the available data.

A material operational discontinuity is evident: the company's primary web domain, Asalyxabio.com, is currently listed for sale on the HugeDomains marketplace for $5,295 (or $220.63/month over 24 months). This is a negative signal that warrants further diligence — it could indicate domain expiry and loss, corporate wind-down, rebranding to an alternate domain, or simply divestiture of a non-essential digital asset — but the source material does not resolve which. Combined with the absence of any post-2021 funding, pipeline, or partnership disclosures, the available evidence points to limited observable forward momentum since the seed round, though the company's underlying operating status cannot be definitively determined from the inputs provided.

Short descriptiontext

Asalyxa Bio is a preclinical-stage, privately held biotech founded in 2020 in Southfield, Michigan, developing neutrophil-targeting therapeutics for diseases with high unmet medical need. The company is venture-funded and has no commercial products or disclosed revenue.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSouthfield, United States
HQ citystring
Southfield
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
neutrophil therapeutics, drug development, inflammatory disease treatments, biopharmaceutical research, targeted drug delivery
Industry1 code
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Therapeutics
Social media profiles1 record
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Asalyxa Bio is an early-stage biopharmaceutical company developing neutrophil-targeting therapeutics aimed at treating diseases with a high unmet medical need. The company's core scientific focus is on engineering drug delivery approaches that leverage neutrophils as a therapeutic vehicle or target for hard-to-treat conditions.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

No product or service information is available. The source data consists solely of a domain marketplace listing (HugeDomains) showing that the domain AsalyxaBio.com is for sale for $5,295. The actual company Asalyxa Bio does not appear to have an operational website or documented product offerings in the available source material.

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
1Prometheus Biosciences
TypeEmerging player
Description

Prometheus Biosciences (acquired by Merck in 2023) developed precision immunology therapeutics for immune-mediated diseases. Comparable as a focused immunology biotech with overlapping therapeutic area.

TypeDirect peer
Description

CytoAgents is a clinical-stage biotech developing neutrophil-targeted therapeutics for inflammatory conditions. It is the closest functional peer to Asalyxa Bio given its focus on modulating neutrophil-driven inflammation.

TypeEmerging player
Description

Cartesian Therapeutics (formerly Selecta Biosciences) develops engineered cell and nanoparticle immunomodulatory therapies for autoimmune and inflammatory disease. Comparable as a small-cap immunology platform company.

TypeBroad incumbent
Description

Eli Lilly has a major immunology portfolio (Taltz, Olumiant) and active R&D in neutrophil-driven autoimmune disease. Comparable as a broad incumbent operating in the same therapeutic category.

TypeEmerging player
Description

Provention Bio (acquired by Sanofi in 2023) developed therapeutics for autoimmune and inflammatory diseases. Comparable as a clinical-stage immunology company with similar indication focus.

TypeEmerging player
Description

Inflammatix develops host-response diagnostics and immunomodulatory therapeutics aimed at dysregulated immune responses in acute and chronic inflammation. Comparable as an emerging immunology-focused company with overlapping therapeutic interests.

TypeEmerging player
Description

Arcturus is a clinical-stage mRNA and delivery-technology company developing therapeutics for rare and inflammatory diseases. Comparable as an emerging platform biotech working on novel immune-cell-directed delivery approaches.

TypeBroad incumbent
Description

AbCellera operates an antibody discovery platform that partners with pharma to develop biologic therapeutics, including immunology programs. Comparable at the biologic-platform level, though at meaningfully greater scale and capitalization.

TypeBroad incumbent
Description

AbbVie operates one of the largest immunology franchises (Humira, Skyrizi, Rinvoq) addressing inflammatory conditions involving neutrophil biology. Comparable as a broad incumbent that dominates the same therapeutic space.

TypeDirect peer
Description

XBiotech develops monoclonal antibody therapeutics targeting inflammation and immune-mediated disease, including indications involving neutrophil biology. Comparable as a small-cap inflammation biotech with a biologic pipeline.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Asalyxa Bio

Biopharmaceutical Therapeuticsasalyxabio.com

Asalyxa Bio is a preclinical-stage, privately held biotech founded in 2020 in Southfield, Michigan, developing neutrophil-targeting therapeutics for diseases with high unmet medical need. The company is venture-funded and has no commercial products or disclosed revenue.

What Asalyxa Bio does

Asalyxa Bio is a privately held, preclinical-stage biotechnology company founded in 2020 and headquartered in Southfield, Michigan. The company is focused on developing therapeutics that target neutrophils — the most abundant class of white blood cells and central effectors of inflammatory and innate immune responses — for application in diseases characterized by high unmet medical need. According to available firmographic data, the company employs between 11 and 50 people and operates as a for-profit entity with no public-market listing. The technology platform is positioned as a neutrophil-targeting drug delivery or modulation approach, but the available input contains no detailed description of the underlying scientific mechanism, specific product candidates, target indications, development stage, or intellectual property estate (no patents or trademarks were disclosed).

The company is led by a four-person executive team composed of co-founder and CSO Lola Eniola-Adefeso — whose background appears rooted in biomedical engineering research — alongside co-founder and CEO Marc Appel, Chief Operating Officer Ryan Fox, and Head of Corporate Development John Freshley. This composition is consistent with an early-stage biotech balancing scientific leadership with operational and business development capacity. There are no disclosed clinical trial programs, partnerships, licensing deals, or commercial products in the source data, and the company's revenue model is not articulated. Asalyxa Bio's only documented capital event is a $2,000,000 seed funding round closed on February 23, 2021, led by Research Bridge Partners with participation from Ann Arbor SPARK, Biosciences Research and Commercialization Center (BRCC), Invest Detroit Ventures, LoftyInc Capital, Michigan Rise, and Woodward Angels. As is typical for early-stage biotech, the implied business model is venture-funded R&D with eventual value realization through outlicensing, partnership, acquisition, or independent commercialization — none of which have materialized in the available data.

A material operational discontinuity is evident: the company's primary web domain, Asalyxabio.com, is currently listed for sale on the HugeDomains marketplace for $5,295 (or $220.63/month over 24 months). This is a negative signal that warrants further diligence — it could indicate domain expiry and loss, corporate wind-down, rebranding to an alternate domain, or simply divestiture of a non-essential digital asset — but the source material does not resolve which. Combined with the absence of any post-2021 funding, pipeline, or partnership disclosures, the available evidence points to limited observable forward momentum since the seed round, though the company's underlying operating status cannot be definitively determined from the inputs provided.

Asalyxa Bio firmographics

Firmographics
Name
Asalyxa Bio
Legal name
Asalyxa Bio
Website
https://asalyxabio.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Asalyxa Bio is a preclinical-stage, privately held biotech founded in 2020 in Southfield, Michigan, developing neutrophil-targeting therapeutics for diseases with high unmet medical need. The company is venture-funded and has no commercial products or disclosed revenue.
Ownership category
akta.pro rank

Asalyxa Bio industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Neutrophil therapeutics
  • Drug development
  • Inflammatory disease treatments
  • Biopharmaceutical research
  • Targeted drug delivery

Where Asalyxa Bio is headquartered

Location

Headquarters

HQ city
Southfield
HQ country
United States
HQ region
North America

Markets served

Asalyxa Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

Asalyxa Bio product offering

Product offering

Core offering

Asalyxa Bio is an early-stage biopharmaceutical company developing neutrophil-targeting therapeutics aimed at treating diseases with a high unmet medical need. The company's core scientific focus is on engineering drug delivery approaches that leverage neutrophils as a therapeutic vehicle or target for hard-to-treat conditions.

Product overview

No product or service information is available. The source data consists solely of a domain marketplace listing (HugeDomains) showing that the domain AsalyxaBio.com is for sale for $5,295. The actual company Asalyxa Bio does not appear to have an operational website or documented product offerings in the available source material.

Differentiator

Problem solved

Functional benefit

Companies that use Asalyxa Bio

Customer profile

Ideal customer profiles1 record

Asalyxa Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Asalyxa Bio partnerships and signals

Strategic signal

Recent moves1 record

Expansion highlights2 records

Asalyxa Bio competitors and assessment

Company assessment

Emerging players

  • Prometheus Biosciences: Prometheus Biosciences (acquired by Merck in 2023) developed precision immunology therapeutics for immune-mediated diseases. Comparable as a focused immunology biotech with overlapping therapeutic area.
  • Cartesian Therapeutics: Cartesian Therapeutics (formerly Selecta Biosciences) develops engineered cell and nanoparticle immunomodulatory therapies for autoimmune and inflammatory disease. Comparable as a small-cap immunology platform company.
  • Provention Bio: Provention Bio (acquired by Sanofi in 2023) developed therapeutics for autoimmune and inflammatory diseases. Comparable as a clinical-stage immunology company with similar indication focus.
  • Inflammatix: Inflammatix develops host-response diagnostics and immunomodulatory therapeutics aimed at dysregulated immune responses in acute and chronic inflammation. Comparable as an emerging immunology-focused company with overlapping therapeutic interests.
  • Arcturus Therapeutics: Arcturus is a clinical-stage mRNA and delivery-technology company developing therapeutics for rare and inflammatory diseases. Comparable as an emerging platform biotech working on novel immune-cell-directed delivery approaches.

Direct peers

  • CytoAgents: CytoAgents is a clinical-stage biotech developing neutrophil-targeted therapeutics for inflammatory conditions. It is the closest functional peer to Asalyxa Bio given its focus on modulating neutrophil-driven inflammation.
  • XBiotech: XBiotech develops monoclonal antibody therapeutics targeting inflammation and immune-mediated disease, including indications involving neutrophil biology. Comparable as a small-cap inflammation biotech with a biologic pipeline.

Broad incumbents

  • Eli Lilly: Eli Lilly has a major immunology portfolio (Taltz, Olumiant) and active R&D in neutrophil-driven autoimmune disease. Comparable as a broad incumbent operating in the same therapeutic category.
  • AbCellera: AbCellera operates an antibody discovery platform that partners with pharma to develop biologic therapeutics, including immunology programs. Comparable at the biologic-platform level, though at meaningfully greater scale and capitalization.
  • AbbVie: AbbVie operates one of the largest immunology franchises (Humira, Skyrizi, Rinvoq) addressing inflammatory conditions involving neutrophil biology. Comparable as a broad incumbent that dominates the same therapeutic space.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

Asalyxa Bio social profiles

Digital presence

Asalyxa Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Asalyxa Bio leadership team

Management profile

Number of profiles

Profiles4 records

Asalyxa Bio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Asalyxa Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Asalyxa Bio

What does Asalyxa Bio do?

Asalyxa Bio is an early-stage biopharmaceutical company developing neutrophil-targeting therapeutics aimed at treating diseases with a high unmet medical need. The company's core scientific focus is on engineering drug delivery approaches that leverage neutrophils as a therapeutic vehicle or target for hard-to-treat conditions.

When was Asalyxa Bio founded?

Asalyxa Bio was founded in 2020. It employs 11 to 50 people.

Where is Asalyxa Bio based?

Asalyxa Bio is headquartered in Southfield, United States, in the North America region.

Who are Asalyxa Bio's main competitors?

Emerging players on record are Prometheus Biosciences, Cartesian Therapeutics, Provention Bio, Inflammatix and Arcturus Therapeutics. Direct peers are CytoAgents and XBiotech. Broad incumbents are Eli Lilly, AbCellera and AbbVie.

Does Asalyxa Bio have an API?

No public API is recorded for Asalyxa Bio.

What industry is Asalyxa Bio in?

Asalyxa Bio's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireResearch Bridge Partners' Seed Capital Investment in Asalyxa Bio Advances Dr. Lola Eniola-Adefeso's Immune Cell Targeted Therapeutic PlatformResearch Bridge Partners, a 501(c)(3) organization bridging research universities with Silicon Valley commercialization resources, announced a seed capital investment in Asalyxa Bio, a University of Michigan spinout developing a drug-delivery technology for inflammatory diseases. The investment will fund development of Asalyxa Bio's lead program ASX-100, which delivers anti-inflammatory agents directly to overreactive neutrophils, with the first indication targeting ARDS—a condition affecting 500,000 Americans annually with no approved drugs currently available. As part of the deal, James Graham joined Asalyxa Bio's board of directors.PR NewswireAsalyxa Bio Closes Seed Financing to Advance Lead Program into First-in-Human Clinical StudiesAsalyxa Bio, a biopharmaceutical company developing nano-engineered immune cell-targeted therapeutics, closed an over-subscribed seed financing round totaling more than $2 million, led by Research Bridge Partners and co-led by ID Ventures with participation from several Michigan-based investors. The proceeds will advance the company's lead development candidate ASX-100 into first-in-human clinical trials for the treatment of Acute Respiratory Distress Syndrome, a condition affecting approximately 500,000 Americans annually with no approved pharmaceutical treatments and a 50% fatality rate. James Graham of Research Bridge Partners has joined Asalyxa Bio's board of directors as part of the financing.GlobeNewswireAsalyxa Bio Launches with Novel Neutrophil-Targeting Drug Delivery Platform Technology and Lead Candidate, ASX-100, for Acute Respiratory Distress Syndrome (ARDS) and COVID-19 PatientsAsalyxa Bio, a University of Michigan spinout, announced its formation and seed funding to advance ASX-100 into first-in-human trials in 2021. ASX-100 is a polymer particle that degrades into salicylic acid, targeting neutrophils to treat ARDS and COVID-19-related ARDS, affecting about 500,000 Americans annually.